Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium
Orioli et al.
, Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective..
, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.12.020
Small retrospective study of 73 diabetic patients in Belgium, 55 HCQ patients, showing HCQ RR 0.87, p
Although the 13% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%]
from meta analysis of the 232 mortality results to date
risk of death, 12.7% lower, RR 0.87, p = 1.00, treatment 8 of 55 (14.5%), control 3 of 18 (16.7%), NNT 47.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Orioli et al., 14 Dec 2020, retrospective, Belgium, peer-reviewed, 9 authors.
Abstract: Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 149e157
Contents lists available at ScienceDirect
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
journal homepage: www.elsevier.com/locate/dsx
Clinical characteristics and short-term prognosis of in-patients with
diabetes and COVID-19: A retrospective study from an academic
center in Belgium
Laura Orioli a, d, *, Thomas Servais a, Leïla Belkhir b, Pierre-François Laterre c,
Jean-Paul Thissen a, d, Bernard Vandeleene a, Dominique Maiter a, d, Jean C. Yombi b, 1,
Michel P. Hermans a, 1
Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200, Brussels, Belgium
Department of Internal Medicine, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200, Brussels, Belgium
Department of Acute Medicine, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200, Brussels, Belgium
Department of Endocrinology, Diabetology and Nutrition, IREC, UCLouvain, Avenue Hippocrate 55, 1200, Brussels, Belgium
a r t i c l e i n f o
s t r u c t u r e d a b s t r a c t
Received 1 December 2020
Received in revised form
5 December 2020
Accepted 9 December 2020
Background and aims: We describe the characteristics and short-term prognosis of in-patients with
diabetes and COVID-19 admitted to a Belgian academic care center.
Methods: We retrospectively reviewed the data on admission from patients with known or newlydiagnosed diabetes and conﬁrmed COVID-19. First, survivors were compared to non-survivors to study
the predictive factors of in-hospital death in patients with diabetes. Secondly, diabetic patients with
SARS-CoV-2 pneumonia were matched for age and sex with non-diabetic patients with SARS-CoV-2
pneumonia, to study the prognosis and predictive factors of in-hospital death related to diabetes.
Results: Seventy-three diabetic patients were included. Mean age was 69 (±14) years. Women accounted
for 52%. Most patients had type 2 diabetes (89.0%), long-term complications of hyperglycemia (59.1%),
and hypertension (80.8%). The case-fatality rate (CFR) was 15%. Non-survivors had more severe pneumonia based on imaging (p 0.029) and were less often treated with metformin (p 0.036). In patients with
SARS-CoV-2 pneumonia, CFR was 15.6% in diabetic (n ¼ 64) and 25.0% in non-diabetic patients (n ¼ 128),
the difference being non-signiﬁcant (p 0.194). Predictive factors of in-hospital death were elevated white
blood cells count (HR 9.4, CI 1.50e58.8, p 0.016) and severe pneumonia on imaging (HR 25.0, CI 1.34
e466, p 0.031) in diabetic patients, and cognitive impairment (HR 5.80, CI 1.61e20.9, p 0.007) and
cardiovascular disease (HR 5.63, CI 1.54e20.6, p 0.009) in non-diabetic patients.
Conclusion: In this monocentric cohort from Belgium, diabetic in-patients with COVID-19 had mostly
type 2 diabetes, prevalent hyperglycemia-related vascular complications and comorbidities including
hypertension. In this cohort, the CFR was not statistically different between patients with and without
© 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.